North America Neisseriaceae Infections Market

North America Neisseriaceae Infections Market Size (2023 to 2028)

The size of the Neisseriaceae Infections market in North America is estimated to hike at a promising CAGR from 2023 to 2028.

During the forecast period, the North American Neisseriaceae infections market is expected to grow steadily. Many factors, such as the rising prevalence of Neisseriaceae infections and continuous R&D procedures in North America, are predicted to fuel this regional market growth. In addition, increases in the incidence of Neisseria gonorrhea infections are likely due in part to increased screening and the introduction of more sensitive and precise screening tools such as Nucleic Acid Amplification (NAAT) Tests.

The rising frequency of gonorrhea and the introduction of innovative diagnostic technologies are projected to propel the gonorrhea therapies market forward. Additionally, as the prevalence of homosexuality and bisexuality has grown, so has the risk of gonorrhea. These variables are bolstered by expanding public knowledge of infections and diseases and rising medical costs. As a result of these factors, the market is predicted to grow at a steady pace.

Laboratory tests are extremely sensitive, but their high costs and technical requirements make them challenging to utilize regularly, limiting their potential impact on STI control and management. Because of the rising prevalence and knowledge of Neisseriaceae-related disorders and their long-term consequences. Furthermore, the increased prevalence of infectious diseases is the most significant issue impeding the market's expansion to a higher end. On the other hand, obstacles such as government austerity, costly treatment, and R&D costs, and a lack of awareness about the symptoms may limit the market's growth to some extent.

This research report on the North America Neisseriaceae infections market has been segmented and sub-segmented into the following categories:

By Type of Bacteria:

• N. Meningitidis     
• N. Gonorrhoeae  
• N. Sicca    
• N. Flava   
• N. Elongata            
• N. Cinerea              
• Others     

By Disease:

• Gonorrhea              
• Septicemia              
• Meningitis               
• Sinusitis    
• Otitis          
• Pneumonia             
• CNS            
• Urinary     
• Respiratory Infections

By Antibacterial Drugs:

• Aminoglycosides (Streptomycin)
• B-Lactum Antibiotics (Penicillin)
• Clavulanic Acid (Augmentin)
• Glycopeptides (Vancomycin)
• Polypeptides (Bacitracin)
• Rifamycins (Rifampicin)
• Chloramphenicol
• Tetracycline

By Country:

• The United States
• Canada
• Rest of North America

Regionally, at present, North America is the most prominent market, owing to the growing prevalence of various Neisseriaceae infections and associated diseases. As a result, North America is expected to have the most significant share of the worldwide market during the forecast period. According to the Centers for Disease Control and Prevention (CDC), more than 300,000 new cases of gonorrhea were recorded in the United States in 2012, up 4% from 2011. As a result, the increased prevalence of infections is a key market development factor. Furthermore, due to extensive R&D practices, a large number of medications and formulations are expected to hit the market between 2016 and 2020.

North America is currently the most dominating regional market because of the rising prevalence of various Neisseriaceae infections and accompanying diseases. However, several countries in the region, such as the United States and Canada, are predicted to grow rapidly during the forecast period.

KEY MARKET PLAYERS:

Companies playing a notable role in the North America Neisseriaceae infections market profiled in this report are Aphios Corporation, Basilea Pharmaceuticals Ltd., Pfizer, Inc., GSK plc, AstraZeneca plc, Adenium Biotech ApS, Dainippon Sumitomo Pharma Co., Ltd., Theravance, Inc., and Pfizer, Inc. amongst many others.